EA200200166A1 - Биодоступная лекарственная форма изотретиноина - Google Patents

Биодоступная лекарственная форма изотретиноина

Info

Publication number
EA200200166A1
EA200200166A1 EA200200166A EA200200166A EA200200166A1 EA 200200166 A1 EA200200166 A1 EA 200200166A1 EA 200200166 A EA200200166 A EA 200200166A EA 200200166 A EA200200166 A EA 200200166A EA 200200166 A1 EA200200166 A1 EA 200200166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cis
isotretinoin
vitamin
bioavailability
bioaccessible
Prior art date
Application number
EA200200166A
Other languages
English (en)
Other versions
EA004808B1 (ru
Inventor
Абха Пант
Индердип Бхатия
Суниленду Бхусхан Рой
Раджив Малик
Original Assignee
Рэнбакси Лабораториз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рэнбакси Лабораториз Лимитед filed Critical Рэнбакси Лабораториз Лимитед
Publication of EA200200166A1 publication Critical patent/EA200200166A1/ru
Publication of EA004808B1 publication Critical patent/EA004808B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к биодоступной фармацевтической композиции на основе кислотной формы 13-цис-витамина А (также известной как 13-цис-ретиноевая кислота или изотретиноин) и способу ее получения. Кислотная форма 13-цис-витамина А является относительно нерастворимым в воде веществом, которое разлагается под действием света и атмосферного кислорода. Нестабильность и относительная нерастворимость затрудняют биодоступность этого лекарственного вещества при пероральном введении, что всегда вызывало проблемы у фармацевтов при разработке композиций. Таким образом желательно создать лекарственную форму, которая обеспечивает стабильность и предсказуемую биодоступность данного лекарственного вещества.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200166A 2000-06-16 2001-04-09 Биодоступная лекарственная форма изотретиноина EA004808B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN596DE2000 IN192188B (ru) 2000-06-16 2000-06-16
PCT/IB2001/000581 WO2001095886A1 (en) 2000-06-16 2001-04-09 Bioavailable dosage form of isotretinoin

Publications (2)

Publication Number Publication Date
EA200200166A1 true EA200200166A1 (ru) 2002-10-31
EA004808B1 EA004808B1 (ru) 2004-08-26

Family

ID=11097063

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200166A EA004808B1 (ru) 2000-06-16 2001-04-09 Биодоступная лекарственная форма изотретиноина

Country Status (25)

Country Link
US (1) US6740337B2 (ru)
EP (1) EP1294357A1 (ru)
JP (1) JP2004503493A (ru)
CN (1) CN1196475C (ru)
AP (1) AP2002002423A0 (ru)
AU (1) AU782094B2 (ru)
BG (1) BG106414A (ru)
BR (1) BR0106752A (ru)
CA (1) CA2382065A1 (ru)
CZ (1) CZ2002694A3 (ru)
EA (1) EA004808B1 (ru)
EE (1) EE200200074A (ru)
HK (1) HK1052302A1 (ru)
HR (1) HRP20020148A2 (ru)
HU (1) HUP0203717A3 (ru)
IL (1) IL148176A0 (ru)
IN (1) IN192188B (ru)
MX (1) MXPA02001669A (ru)
NZ (1) NZ517142A (ru)
OA (1) OA12008A (ru)
PL (1) PL352838A1 (ru)
SK (1) SK2252002A3 (ru)
UA (1) UA74793C2 (ru)
WO (1) WO2001095886A1 (ru)
ZA (1) ZA200201240B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423170A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
MXPA05012632A (es) * 2003-05-20 2006-02-22 Ranbaxy Lab Ltd Composiciones farmaceuticas de acitretin.
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
EP2123255B1 (en) * 2007-02-16 2013-05-15 ASKA Pharmaceutical Co., Ltd. Pharmaceutical composition containing fine particle oil-based suspension
US7763748B2 (en) * 2007-02-20 2010-07-27 Ipca Laboratories Limited Process for preparation of highly pure isotretinoin
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
MX2017015137A (es) * 2015-05-25 2018-03-28 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de dosis diaria de isotretinoin.
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
CA1282326C (en) * 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US4808630A (en) * 1987-01-16 1989-02-28 United States Of America Method of treating psychotic illnesses
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
PE20001227A1 (es) 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof

Also Published As

Publication number Publication date
AU782094B2 (en) 2005-06-30
ZA200201240B (en) 2002-09-02
CZ2002694A3 (cs) 2002-08-14
AP2002002423A0 (en) 2002-03-31
PL352838A1 (en) 2003-09-08
CN1196475C (zh) 2005-04-13
HUP0203717A3 (en) 2003-05-28
HUP0203717A2 (hu) 2003-04-28
IL148176A0 (en) 2002-09-12
US20020025338A1 (en) 2002-02-28
BG106414A (en) 2002-09-30
EP1294357A1 (en) 2003-03-26
EE200200074A (et) 2003-04-15
IN192188B (ru) 2004-03-13
US6740337B2 (en) 2004-05-25
BR0106752A (pt) 2002-04-16
JP2004503493A (ja) 2004-02-05
NZ517142A (en) 2003-08-29
CA2382065A1 (en) 2001-12-20
MXPA02001669A (es) 2002-08-06
OA12008A (en) 2006-04-19
HK1052302A1 (zh) 2003-09-11
HRP20020148A2 (en) 2003-12-31
EA004808B1 (ru) 2004-08-26
UA74793C2 (en) 2006-02-15
AU4445901A (en) 2001-12-24
WO2001095886A1 (en) 2001-12-20
CN1388757A (zh) 2003-01-01
SK2252002A3 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
EA200300752A1 (ru) Фармацевтическая композиция, имеющая сниженную тенденцию кристаллизации лекарственного ингредиента
EA199700267A1 (ru) Применение фумагиллола и его производных для приготовления антиинфекционных интестинальных препаратов и фармацевтическая композиция на их основе
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
BR0207880A (pt) Formulação farmacêutica, processo para preparação da mesma e uso de formulação sólida
ES2048594T3 (es) Formulaciones farmaceuticas.
EA200200166A1 (ru) Биодоступная лекарственная форма изотретиноина
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
CY1110261T1 (el) Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα
DE59009074D1 (de) Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus.
EP1938821A3 (en) Methods of administering epothilone analogs for the treatment of cancer
CA2575587A1 (en) Carrier for enteral administration
FI913949A (fi) Menetelmä substituoidun karboksyylihapon farmaseuttisesti käyttökelpoisen kodeiinisuolan valmistamiseksi
IE902627A1 (en) Pharmaceutical composition for oral administration¹containing nac
KR970025615A (ko) 암 전이 억제제
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
WO2004113391A3 (en) Improved pharmaceutical drug candidates and methods for preparation thereof
HU901095D0 (en) Process for producing compound reducing extraction of gastric acid and pharmaceutical preparative containing said compound
KR970705563A (ko) 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
ATE116969T1 (de) Nmda-antagonisten.
DK0681473T3 (da) Præparater, der indeholder tandospiron eller dets analoger
EA200200610A1 (ru) НОВЫЕ ЗАМЕЩЕННЫЕ ПИРАЗОЛО [4,3-е]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EE200200143A (et) 4-bensüülaminokinoliini konjugaadid sapphappega ja nende heteroanaloogid, nende valmistamismeetod ning neid ühendeid sisaldavad ravimid ja nende kasutamine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU